This special collection provides new insights on major aspects of depression: psychopharmacology, therapeutic interventions, major depressive episodes, biomarkers, and pseudobulbar affect.
A meta-analysis exploring factors associated with quality of life in first-episode psychosis provides guidance and take-home points for clinicians.
ECT is a highly effective treatment for depression, but a portion of patients fail to respond as hoped. Clinical variables have overall limited utility as a predictor of response. Is inflammation the key?
New research suggests that viruses and metals in the brain may exacerbate Alzheimer disease and deep brain stimulation shows promise in slowing cognitive decline.
Although these medication-assisted treatments have been approved by the FDA and have strong empiric evidence for superior outcomes, it is important to know the good and the bad.
Highlights of 3 new studies investigate how to choose the best therapy for depression as well as the negative influences of polypharmacy and social media.
The immune-brain loop: a world where more and more clinicians boldly go—and thrive—among new discoveries.
The neuroprotective role of resilience in patients with schizophrenia who experienced early childhood trauma is evaluated in this brief update.
This month's roundup features noteworthy stories from around the web: the humanitarian crisis at the border, new gaming disorder diagnosis, a medication investigation of over 26,000 adult patients, a boundary-busting neurologist, and physician and celebrity suicides.
Revival of an old drug, declaration of independence for seniors, inmates doing more than time—these and other stories are covered in our monthly roundup.